TRIMTECH Therapeutics
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
$47MSeed+
Role not disclosedCE
Cambridge Enterprise Ventures
Activity from announced rounds
Activity in this selectionUnited Kingdom · Oct 23, 2026 · Jan 1, 2026
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 4 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $84M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionGigaton
Develops AI-driven control software for energy-intensive industries
$26MSeries A
Role not disclosedSemarion
Develops next-generation cell assay technology for drug discovery
$3.8MUndisclosed
Role not disclosedxWatts
Develops AI-driven energy management software to optimize energy use in real estate portfolios
£1.6MSeed
Role not disclosedSparxell
Sparxell makes plant-based pigments whose microscopic structure creates colour without conventional synthetic dyes.
$5MPre-Series A
Participant